Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97541596

Filing Date: 08/09/2022

To the Commissioner for Trademarks:

MARK: KRAZATI (stylized and/or with design, see mark)
The literal element of the mark consists of KRAZATI. The mark consists of the stylized term "KRAZATI".
The applicant, Mirati Therapeutics, Inc., a corporation of Delaware, having an address of
      3545 Cray Court
      San Diego, California 92121
      United States
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 042:  research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.




The owner's/holder's proposed attorney information: Eric R. Moran. Other appointed attorneys are All other attorneys at McDonnell Boehnen Hulbert & Berghoff LLP. Eric R. Moran of McDonnell Boehnen Hulbert & Berghoff LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      31st Floor
      300 South Wacker Drive
      Chicago, Illinois 60606
      United States
      312-913-0001 x3302(phone)
      312-913-0002(fax)
      docketing@mbhb.com
The docket/reference number is 22-1287-US.
Eric R. Moran submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Eric R. Moran

PRIMARY EMAIL FOR CORRESPONDENCE: docketing@mbhb.com        SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): moran@mbhb.com; potempam@mbhb.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $700 has been submitted with the application, representing payment for 2 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /Eric R. Moran/   Date: 08/09/2022
Signatory's Name: Eric R. Moran
Signatory's Position: Attorney of record, Illinois bar member
Signatory's Phone Number: 312-913-3302
Signature method: Signed directly within the form
Payment Sale Number: 97541596
Payment Accounting Date: 08/09/2022

Serial Number: 97541596
Internet Transmission Date: Tue Aug 09 17:31:51 ET 2022
TEAS Stamp: USPTO/BAS-XX.XXX.XXX.XX-2022080917315145
5949-97541596-8207730e0fef9432126cd80c0c
6c5d99401b1bc45932db29ffdb32dcd8d23c-CC-
31501314-20220809172055204193